Megola Inc banner
M

Megola Inc
OTC:MGON

Watchlist Manager
Megola Inc
OTC:MGON
Watchlist
Price: 0.17 USD -10.53% Market Closed
Market Cap: $540k

EV/FCFF

0
Current
No historical data
Comparison unavailable

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
0
=
Enterprise Value
$0
/
Free Cash Flow to Firm
$0

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
0
=
Enterprise Value
$0
/
Free Cash Flow to Firm
$0

Valuation Scenarios

Megola Inc is trading above its industry average

If EV/FCFF returns to its Industry Average (19.8), the stock would be worth $0 (100% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-100%
Maximum Upside
No Upside Scenarios
Average Downside
100%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 0 $0.17
0%
Industry Average 19.8 $0
-100%
Country Average 23.2 $0
-100%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
US
Megola Inc
OTC:MGON
540k USD 0 0
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 140.4 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 29.1 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 34.8 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 19 19.5
US
Merck & Co Inc
NYSE:MRK
274.6B USD 24.8 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 42.2 11.1
US
Pfizer Inc
NYSE:PFE
149.3B USD 21.8 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 11.6 16.4
P/E Multiple
Earnings Growth PEG
US
M
Megola Inc
OTC:MGON
Average P/E: 21.5
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1

Market Distribution

Not Available
No Country distribution data available for this multiple

Megola Inc
Glance View

Market Cap
540k USD
Industry
Pharmaceuticals

Megola, Inc. is a consortium group of health technologies and service company. The company is headquartered in Bonita Springs, Florida. The company went IPO on 2002-12-12. The company has the following product lines: physical water treatment, air purification and fire safety. Megola provides environmental solutions through advanced technology and solves environmental problems. The Company’s principal product is the ScaleGuard Water treatment product line. Megola’s ScaleGuard technology conditions hard water and eliminates the scale caused by hard water in residential, commercial and industrial applications. ScaleGuard units use electromagnetic technology to condition the soften water, both preventing the ongoing build‐up of scale and eliminating scale build‐up in water delivery systems and machinery. The company has a wholly-owned subsidiary, MedCan Marijuana Inc., which is engaged in providing capital to medical marijuana related businesses.

MGON Intrinsic Value
Not Available
M
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett